Suppr超能文献

[假药——日本与世界]

[Counterfeit medicines--Japan and the world].

作者信息

Sato Daisaku

机构信息

Office of Compliance, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare.

出版信息

Yakugaku Zasshi. 2014;134(2):213-22. doi: 10.1248/yakushi.13-00230-3.

Abstract

Circulating counterfeit medicines in the market is a public health threat. Counterfeit medicines become common problem, not only in developing countries, but also in industrialised countries, as internet has made them more accessible. In Japan, the recent survey on the medicines purchased through on-line pharmacy (targeting Japanese consumers) showed that the majority of erectile dysfunction (ED) medicines imported by individuals in Japan were counterfeit version. The survey of Japanese consumers, who privately imported medicines through on-line pharmacy, indicated that 16% of these consumers experienced adverse events associated with these products. Not only that it is just fake brand, but fake medicines may even cause health hazard. The counterfeit version of Avastin recently detected in the United States became a serious threat for those who desperately need these medicines for life-threatening disease. The Japanese regulatory authorities have provided risk information of counterfeit medicines to general public, as well as monitored on-line pharmacies and conducted enforcement action where necessary. However, more resources of compliance activity should be allocated to respond to the situation of growing threats of counterfeit medicines. Purchasing medicines from abroad through unauthorised channel is the major source of counterfeit medicines. It is essential to prevent circulation of counterfeit medicines through international collaboration of various regulatory authorities. To address these problems, the World Health Organization (WHO) has launched a new Member States Mechanism (MSM) to build network of the authorities. Also, INTERPOL (ICPO) initiated globally concerted enforcement actions (Operation Pangea) against pharmaceutical crime as well as built partnership with pharmaceutical industry to create Pharmaceutical Crime Programme. It is also necessary to prevent consumers encountering counterfeit medicines and to prevent health hazard. The Ministry of Health, Labour and Welfare (MHLW) has been actively involved in prevention and educational activities such as public awareness campaign. MHLW started anti-counterfeit medicines and new psychoactive substance project from February 2013, which centrally collects information about counterfeit medicines, in particular, and provides the risk information more effectively to the public. Japanese Government will work together with international community and contribute to combating counterfeiting through public and private partnership.

摘要

市场上流通的假药是对公众健康的一种威胁。假药已成为一个普遍问题,不仅在发展中国家存在,在工业化国家也很常见,因为互联网使假药更容易获取。在日本,最近一项针对通过网上药店购买的药品(针对日本消费者)的调查显示,日本个人进口的大多数勃起功能障碍(ED)药物都是假冒版本。对通过网上药店私自进口药品的日本消费者的调查表明,这些消费者中有16%经历了与这些产品相关的不良事件。假药不仅只是假冒品牌,甚至可能对健康造成危害。最近在美国检测到的阿瓦斯汀假冒版本,对那些急需这些药物治疗危及生命疾病的人构成了严重威胁。日本监管当局已向公众提供假药风险信息,同时对网上药店进行监测,并在必要时采取执法行动。然而,应分配更多的合规活动资源,以应对假药威胁不断增加的形势。通过未经授权的渠道从国外购买药品是假药的主要来源。通过各监管当局的国际合作防止假药流通至关重要。为解决这些问题,世界卫生组织(WHO)启动了一个新的成员国机制(MSM),以建立各当局的网络。此外,国际刑警组织(ICPO)发起了针对药品犯罪的全球协同执法行动(“盘古行动”),并与制药行业建立伙伴关系,以创建药品犯罪项目。防止消费者遇到假药并预防健康危害也很有必要。厚生劳动省一直积极参与预防和教育活动,如公众宣传运动。厚生劳动省从2013年2月开始实施打击假药和新型精神活性物质项目,该项目特别集中收集有关假药的信息,并更有效地向公众提供风险信息。日本政府将与国际社会共同努力,通过公私伙伴关系为打击假冒行为做出贡献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验